Targeting interleukin-6/glycoprotein-130 signaling by raloxifene or sc144 enhances paclitaxel efficacy in pancreatic cancer

HIGHLIGHTS

• who: Nina A. Hering et al. from the Department of General and Visceral Surgery, Charitu00e9-Universitu00e4tsmedizin Berlin, Corporate Member of Freie Universitu00e4t Berlin and Humboldt-Universitu00e4t zu Berlin, Berlin, Germany IU Health University, Mainz, Germany have published the Article: Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic Cancer, in the Journal: Cancers 2023, 456 of /2023/
• what: This study aimed to clarify if the interleukin-6/glycoprotein130 signaling cascade using the small-molecule gp130 inhibitor or raloxifene a non-steroidal selective estrogen receptor modulator enhances paclitaxel efficacy. Improving . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.